Identification and Validation of Apparent Imbalanced Epi-lncRNAs Prognostic Model Based on Multi-Omics Data in Pancreatic Cancer

Ke, Mujing

doi:10.3389/fmolb.2022.860323

Cited by 7 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In PC, LINC00941 expression was found to be higher in pancreatic cancer tissues, and its localization was primarily observed in the cytosol of tumor cells. LINC00941 expression positively correlated with advanced pathological features [36,40,42], and higher expression levels of LINC00941 were associated with unfavorable prognoses in PC patients [36,37,40,42,43,48,49], further highlighting its significance as a prognostic biomarker for PC. Overall, the consistent upregulation of LINC00941 in various gastrointestinal cancers and its association with clinical features and patient outcomes shows its potential as a valuable biomarker for diagnosis, prognosis and risk assessment of these diseases.…”

Section: Studies With Clinical Patient Samplesmentioning

confidence: 87%

“…LINC00941 has been studied in various GI cancer types, including squamous cell carcinoma (ESCC) [35,39], gastric cancer (GC) [45,46], colorectal cancer (CRC) [41,44], hepatocellular carcinoma (HCC) [47], and pancreatic cancer (PC) [36,37,40,42,43,48,49]. Research have shown that LINC00941 plays a regulatory role in GI development by influencing key molecules and genes involved in a series of biological processes, such as proliferation, invasion, migration, and EMT (Figure 1).…”

Section: Linc00941 In Gastrointestinal Cancersmentioning

confidence: 99%

“…Depletion of LINC00941 in HCC suppressed xenograft formation and metastasis, leading to smaller tumors and a decreased number of liver nodules [47]. In PC [36,37,40,42,43,48,49]…”

Section: Studies Using Murine Animal Modelsmentioning

confidence: 99%

See 2 more Smart Citations

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers pose a significant global health challenge, characterized by a high incidence and poor prognosis. The delayed detection and occurrence of metastasis contribute to the overall low survival rates associated with these cancers. Therefore, there is an urgent need to identify novel molecular targets for effective GI cancer treatment. Recent research has shed light on the potential of long non-coding RNAs (lncRNAs) as promising targets in cancer therapy, given their strong association with carcinogenesis and profound impact on tumor development. Among these lncRNAs, lncRNA-MUF, also known as LINC00941, has emerged as a key player in oncogenic regulation, specifically implicated in the progression of various GI cancers, including esophageal, gastric, colorectal, hepatic, and pancreatic cancer. This review aims to provide an updated and focused analysis of the regulatory roles of LINC00941 in the initiation and progression of GI cancer. Our objective is to unravel the underlying molecular mechanisms through which LINC00941 influences GI cancer phenotypes both in vivo and in vitro, with a special emphasis on the key molecules and signaling pathways involved. Additionally, LINC00941 has demonstrated clinical significance in terms of clinical pathology, prognosis, and diagnosis in GI tumors, further reinforcing its potential as a novel therapeutic target.

show abstract

Section: Studies With Clinical Patient Samplesmentioning

confidence: 87%

Section: Linc00941 In Gastrointestinal Cancersmentioning

confidence: 99%

See 1 more Smart Citation

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The mechanisms by which LINC00663 regulates tumorigenesis remain unclear. Although LINC00663 can suppress the expression of oncogene ENO1 in breast cancer 37 , it was upregulated in pancreatic cancer and glioma cells, promoting tumor progression 38 , 39 . The roles of ITGA9-AS1 and the interactions among the four lncRNAs have been relatively less studied.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of sialylation-related long non-coding RNAs in lung adenocarcinoma

Wang,

Hou,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

There has been increasing interest in the role of epigenetic modification in cancers recently. Among the various modifications, sialylation has emerged as a dominant subtype implicated in tumor progression, metastasis, immune evasion, and chemoresistance. The prognostic significance of sialylation-related molecules has been demonstrated in colorectal cancer. However, the potential roles and regulatory mechanisms of sialylation in lung adenocarcinoma (LUAD) have not been thoroughly investigated. Through Pearson correlation, univariate Cox hazards proportional regression, and random survival forest model analyses, we identified several prognostic long non-coding RNAs (lncRNAs) associated with aberrant sialylation and tumor progression, including LINC00857, LINC00968, LINC00663, and ITGA9-AS1. Based on the signatures of four lncRNAs, we classified patients into two clusters with different landscapes using a non-negative matrix factorization approach. Collectively, patients in Cluster 1 (C1) exhibited worse prognoses than those in Cluster 2 (C2), as well as heavier tumor mutation burden. Functional enrichment analysis showed the enrichment of several pro-tumor pathways in C1, differing from the upregulated Longevity and programmed cell death pathways in C2. Moreover, we profiled immune infiltration levels of important immune cell lineages in two subgroups using MCPcounter scores and single sample gene set enrichment analysis scores, revealing a relatively immunosuppressive microenvironment in C1. Risk analysis indicated that LINC00857 may serve as a pro-tumor regulator, while the other three lncRNAs may be protective contributors. Consistently, we observed upregulated LINC00857 in C1, whereas increased expressive levels of LINC00968, LINC00663, and ITGA9-AS1 were observed in C2. Finally, drug sensitivity analysis suggested that patients in the two groups may benefit from different therapeutic strategies, contributing to precise treatment in LUAD. By integrating multi-omics data, we identified four core sialylation-related lncRNAs and successfully established a prognostic model to distinguish patients with different characterizations. These findings may provide some insights into the underlying mechanism of sialylation, and offer a new stratification way as well as clinical guidance in LUAD.

show abstract

“…Necroptosis and ferroptosis are newly discovered programmed cell deaths recently [ 47 ]. AL161431.1 acts as an autophagy- and prognosis-relevant lncRNA in NSCLC [ 48 ], with epigenetically aberrant regulation in LUAD [ 49 ] and pancreatic adenocarcinoma [ 50 ]. In addition, AL161431.1 is linked to hypoxia status and immune microenvironment of LUAD [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma

Wang

Yao

Dong

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Objective. Cuproptosis is a newly discovered copper-independent cell death modality, and limited evidence suggests the critical implications in human cancers. Nonetheless, the clinical impacts of cuproptosis-relevant lncRNAs in lung adenocarcinoma (LUAD) remain largely ill-defined. The present study was aimed at defining a cuproptosis-relevant lncRNA signature for LUAD and discuss the clinical utility. Methods. We collected transcriptome expression profiling, clinical information, somatic mutation, and copy number variations from TCGA-LUAD cohort retrospectively. The genetic alterations of cuproptosis genes were systematically assessed across LUAD, and cuproptosis-relevant lncRNAs were screened for defining a LASSO prognostic model. Genomic alterations, immunological and stemness features, and therapeutic sensitivity were studied with a series of computational approaches. Results. Cuproptosis genes displayed aberrant expression and widespread genomic alterations across LUAD, potentially modulated by m6A/m5C/m1A RNA modification mechanisms. We defined a cuproptosis-relevant lncRNA signature, with a reliable efficacy in predicting clinical outcomes. High-risk subset displayed higher somatic mutations, CNVs, TMB, SNV neoantigens, aneuploidy score, CTA score, homologous recombination defects, and intratumor heterogeneity, cytolytic activity, CD8+ T effector, and antigen processing machinery, proving that this subset might benefit from immunotherapy. Increased stemness indexes and activity of oncogenic pathways might contribute to undesirable prognostic outcomes for high-risk subset. Additionally, high-risk patients generally exhibited higher response to chemotherapeutic agents (cisplatin, etc.). We also predicted several small molecule compounds (GSK461364, KX2-391, etc.) for treating this subset. Conclusion. Accordingly, this cuproptosis-relevant lncRNA signature offers an efficient approach to identify and characterize diverse prognosis, genomic alterations, and treatment outcomes in LUAD, thus potentially assisting personalized therapy.

show abstract

Identification and Validation of Apparent Imbalanced Epi-lncRNAs Prognostic Model Based on Multi-Omics Data in Pancreatic Cancer

Cited by 7 publications

References 50 publications

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

The prognostic value of sialylation-related long non-coding RNAs in lung adenocarcinoma

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma

Contact Info

Product

Resources

About